Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
Nasdaq15d
Supernus Pharmaceuticals Announces FDA Approval for Updated Qelbree Label Including New Pharmacodynamic Data and Lactation Information
Supernus Pharmaceuticals, Inc. announced that the FDA has approved an updated label for Qelbree (viloxazine extended-release capsules ... a multi-dose (600 mg daily for three days) regimen ...
Business Insider15d
Supernus announces U.S. FDA approved an update for label for Qelbree
Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to include new pharmacodynamic data in Section 12.2. The ...
Hosted on MSN15d
FDA approves Qelbree label update for ADHD treatment
In other recent news, Supernus Pharmaceuticals reported a notable increase in total revenue, reaching $175.7 million, primarily due to the growth of key products, Qelbree and GOCOVRI. Despite the ...
Yahoo Finance1y
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We’re thrilled to see the impact that Qelbree has had on people living with ADHD, including Jay Glazer, and appreciate his ...